GFAP and Alzheimer disease: When integrated with other pathological markers (e.g., p-tau181, p-tau217, and GFAP), APOA-I may enhance the sensitivity and specificity of diagnostic frameworks for both disease staging and cognitive monitoring in AD, which holds particular significance for AD MDT decisions.